Haldol Decanoas

Haldol Decanoas is a pharmaceutical product containing haloperidol decanoate, supplied as an intramuscular injection. It is a long‑acting formulation of the typical antipsychotic haloperidol, marketed in the European Union. The preparation is intended for prescription use and classified as a dopamine D2 receptor antagonist for managing certain psychiatric conditions. It provides sustained plasma levels, allowing dosing intervals of several weeks, and is administered by a healthcare professional.

Haloperidol decanoate administered as Haldol Decanoas is indicated for several psychiatric indications where long‑acting antipsychotic therapy is appropriate. The intramuscular formulation delivers steady drug concentrations over weeks, supporting both acute and maintenance treatment strategies in adult patients.

- Schizophrenia (maintenance therapy) - Acute psychotic episodes requiring rapid control - Prevention of relapse in patients stabilized on oral haloperidol - Management of severe agitation in psychotic patients - Adjunctive use when oral adherence is problematic

Haloperidol decanoate may cause a range of side effects, some of which are common and generally mild, while others are serious and require prompt medical attention.

Common: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain or increased appetite

Serious: - Extrapyramidal symptoms such as dystonia or akathisia - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome, a rare life‑threatening reaction - Significant orthostatic hypotension or cardiac arrhythmia

When prescribing Haldol Decanoas, clinicians should evaluate patient-specific factors and monitor for potential complications throughout therapy.

- Assess cardiovascular status before initiating therapy - Monitor for signs of movement disorders during treatment - Use caution in patients with a history of seizures - Evaluate liver and renal function periodically - Discuss pregnancy and breastfeeding considerations with the patient - Avoid abrupt discontinuation to reduce withdrawal risk - Consider dose adjustments in elderly patients

Haloperidol decanoate can interact with other medicines, influencing its effectiveness or safety profile. Some combinations should be avoided, while others require careful monitoring.

Avoid: - Concurrent use with other dopamine antagonists may increase extrapyramidal risk - Combining with strong CYP3A4 inhibitors can raise haloperidol levels - Co‑administration with QT‑prolonging agents may heighten cardiac risk

Use with caution: - Moderate CYP3A4 inducers may reduce efficacy; monitor response - Anticholinergic medications can mask early signs of extrapyramidal symptoms - Alcohol or sedatives may enhance central nervous system depression